DSGN Design Therapeutics, Inc.
$14.63▼ -1.15%
Healthcare
Other
After hours
$14.80▲ +1.16%
Sep 11, 6:42 PM ET
Volume 715.2K
Avg Volume (10D) 627.7K
Key Metrics & Fundamentals
Market Cap
$915.57M
P/E Ratio
–
Div Yield
–%
52W Range
5.28 - 17.25
% vs 50 MA
3.55%
% vs 200 MA
24.15%
RSI-14
48.5
MACD Histogram
-0.1500
Beta (1Y vs SPY)
1.19
Free Cash Flow
-$15.55M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$22.03M
COGS
–
Operating Exp
$22.18M
Operating Income
-$22.18M
EBIT
-$22.18M
Pretax Income
-$20.17M
Net Income
-$20.17M
EPS (Diluted)
-0.32
Price & Volume History
Loading chart…
Recent News
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
GlobeNewswire · Sep 2, 2026 12:00 PM
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch
24/7 Wall St. · Aug 27, 2026 2:00 PM
Design Therapeutics Q2 Net Loss Narrows
MT Newswires · Aug 3, 2026 12:43 PM
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
GlobeNewswire · Aug 3, 2026 12:00 PM
Fuchs Endothelial Corneal Dystrophy Market Forecast Highlights Significant Growth During the Forecast Period (2026-2036), Owing to the Expanding Treatment Landscape and Increasing Patient Pool | DelveInsight
PR Newswire · Jul 6, 2026 2:31 PM
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
GlobeNewswire · Jun 30, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See DSGN's money flow as a full page
Social Sentiment
No Reddit posts found for DSGN.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.